SCHEMBL313880

SCHEMBL313880

COc1cccc(-c2nnc3n2-c2ccc(OC)cc2NCC3C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
NPSR1 Q6W5P4 4/20 0.40
MAPT P10636 3/20 0.40
TSHR P16473 3/20 0.40
RAB9A P51151 3/20 0.40
LMNA P02545 2/20 0.40
DCTPP1 Q9H773 1/20 0.40
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 1/20 0.39
PIM1 P11309 1/20 0.39
HIF1A Q16665 3/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
NISCH Q9Y2I1 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MITF O75030 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313881 1.00 ALDH1A1 (0.40) ALDH1A1NPSR1MAPTTSHRRAB9A
SCHEMBL313882 1.00 ALDH1A1 (0.40) ALDH1A1NPSR1MAPTTSHRRAB9A
SCHEMBL314088 0.92 ALDH1A1 (0.45) ALDH1A1DCTPP1DYRK1ACLK4PIM1
SCHEMBL314086 0.92 ALDH1A1 (0.45) ALDH1A1DCTPP1DYRK1ACLK4PIM1
SCHEMBL314087 0.92 ALDH1A1 (0.45) ALDH1A1DCTPP1DYRK1ACLK4PIM1
SCHEMBL314465 0.92 BRD4 (0.40) ALDH1A1TSHRLMNAHPGDMAPK1
SCHEMBL314135 0.92 ALDH1A1 (0.40) ALDH1A1MAPTPIM1MEN1KMT2A
SCHEMBL314464 0.92 BRD4 (0.40) ALDH1A1TSHRLMNAHPGDMAPK1
SCHEMBL314466 0.92 BRD4 (0.40) ALDH1A1TSHRLMNAHPGDMAPK1
SCHEMBL314136 0.92 ALDH1A1 (0.40) ALDH1A1MAPTPIM1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 ALDH1A1 2295/4885NPSR1 2257/4885MAPT 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.